Literature DB >> 15078714

Early physiological response to intensive care as a clinically relevant approach to predicting the outcome in severe acute pancreatitis.

Richard Flint1, John A Windsor.   

Abstract

HYPOTHESIS: The physiological response to treatment is a better predictor of outcome in acute pancreatitis than are traditional static measures.
DESIGN: Retrospective diagnostic test study. The criterion standard was Organ Failure Score (OFS) and Acute Physiology and Chronic Health Evaluation II (APACHE II) score at the time of hospital admission.
SETTING: Intensive care unit of a tertiary referral center, Auckland City Hospital, Auckland, New Zealand. PATIENTS: Consecutive sample of 92 patients (60 male, 32 female; median age, 61 years; range, 24-79 years) with severe acute pancreatitis. Twenty patients were not included because of incomplete data. The cause of pancreatitis was gallstones (42%), alcohol use (27%), or other (31%). At hospital admission, the mean +/- SD OFS was 8.1 +/- 6.1, and the mean +/- SD APACHE II score was 19.9 +/- 8.2.
INTERVENTIONS: All cases were managed according to a standardized protocol. There was no randomization or testing of any individual interventions. MAIN OUTCOME MEASURES: Survival and death.
RESULTS: There were 32 deaths (pretest probability of dying was 35%). The physiological response to treatment was more accurate in predicting the outcome than was OFS or APACHE II score at hospital admission. For example, 17 patients had an initial OFS of 7-8 (posttest probability of dying was 58%); after 48 hours, 7 had responded to treatment (posttest probability of dying was 28%), and 10 did not respond (posttest probability of dying was 82%). The effect of the change in OFS and APACHE II score was graphically depicted by using a series of logistic regression equations. The resultant sigmoid curve suggests that there is a midrange of scores (the steep portion of the graph) within which the probability of death is most affected by the response to intensive care treatment.
CONCLUSION: Measuring the initial severity of pancreatitis combined with the physiological response to intensive care treatment is a practical and clinically relevant approach to predicting death in patients with severe acute pancreatitis.

Entities:  

Mesh:

Year:  2004        PMID: 15078714     DOI: 10.1001/archsurg.139.4.438

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  7 in total

1.  Early organ-specific mitochondrial dysfunction of jejunum and lung found in rats with experimental acute pancreatitis.

Authors:  Anubhav Mittal; Anthony J R Hickey; Chau C Chai; Benjamin P T Loveday; Nichola Thompson; Anna Dare; Brett Delahunt; Garth J S Cooper; John A Windsor; Anthony R J Phillips
Journal:  HPB (Oxford)       Date:  2011-03-29       Impact factor: 3.647

2.  Regulation of omega-3 fish oil emulsion on the SIRS during the initial stage of severe acute pancreatitis.

Authors:  Jiongxin Xiong; Shikai Zhu; Yu Zhou; Heshui Wu; Chunyou Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-02-18

3.  What is New in Acute Pancreatitis?

Authors:  Vivek Vij; Sanjay Singh Negi; Adarsh Chaudhary
Journal:  Med J Armed Forces India       Date:  2011-07-21

Review 4.  Scoring of human acute pancreatitis: state of the art.

Authors:  Guido Alsfasser; Bettina M Rau; Ernst Klar
Journal:  Langenbecks Arch Surg       Date:  2013-05-17       Impact factor: 3.445

5.  The role of open necrosectomy in the current management of acute necrotizing pancreatitis: a review article.

Authors:  K Vasiliadis; C Papavasiliou; A Al Nimer; N Lamprou; C Makridis
Journal:  ISRN Surg       Date:  2013-01-28

Review 6.  Predicting severity of acute pancreatitis.

Authors:  Bettina M Rau
Journal:  Curr Gastroenterol Rep       Date:  2007-04

7.  Pancreatitis cytosorbents (CytoSorb) inflammatory cytokine removal: A Prospective Study (PACIFIC).

Authors:  Wolfgang Huber; Hana Algül; Tobias Lahmer; Ulrich Mayr; Miriam Lehmann; Roland M Schmid; Andreas Faltlhauser
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.